Skip to main content
logo
Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
1.330
+0.210 (18.75%)
At close: Sep 15, 2026, 4:00 PM EDT
1.270
-0.060 (-4.51%)
Pre-market: Sep 16, 2026, 7:26 AM EDT

Biodexa Pharmaceuticals Income Statement

Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.380.70.58
Revenue Growth
----45.49%20.93%68.51%
Cost of Revenue
3.963.965.444.075.114.65
Gross Profit
-3.96-3.96-5.44-3.69-4.41-4.08
Selling, General & Admin
4.24.843.794.344.542.95
Research & Development
1.25-----
Other Operating Expenses
-0.57-0.15-0.03-0.01-0.02-0.02
Operating Expenses
4.884.683.764.334.522.92
Operating Income
-8.84-8.65-9.2-8.01-8.93-7
Interest Expense
-0.16-0.23-0.17-0.04-0.05-0.04
Interest & Investment Income
0.090.090.170.080.03-
Other Non Operating Income (Expenses)
4.592.33.220.490.470.94
EBT Excluding Unusual Items
-4.32-6.49-5.98-7.49-8.49-6.11
Pretax Income
-4.32-6.49-5.98-7.49-8.49-6.11
Income Tax Expense
0.1-0.11-0.25-0.41-0.83-0.65
Earnings From Continuing Operations
-4.42-6.38-5.73-7.08-7.66-5.46
Net Income
-4.42-6.38-5.73-7.08-7.66-5.46
Net Income to Common
-4.42-6.38-5.73-7.08-7.66-5.46
Net Income Growth
------
Shares Outstanding (Basic)
-0----
Shares Outstanding (Diluted)
-0----
Shares Change
------
EPS (Basic)
--58.18----
EPS (Diluted)
--58.18----
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-6.91-5.59-12.27-6.85-7.11-6.33
Free Cash Flow Per Share
--50.97----
Operating Margin
----2103.41%-1277.83%-1210.73%
Profit Margin
----1858.01%-1095.28%-944.64%
Free Cash Flow Margin
----1798.42%-1017.17%-1094.81%
EBITDA
-8.85-8.59-9.08-7.87-8.76-6.79
D&A For EBITDA
-0.010.050.120.140.170.21
EBIT
-8.84-8.65-9.2-8.01-8.93-7
SEC Filings: 10-K · 10-Q